Press Releases

Bio-Thera Solutions, Ltd., a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase I clinical study to compare the pharmacokinetics and safety of BAT1308, a monoclonal antibody targeting PD-1 in cancer patient volunteers. “PD-1 is a validated drug target. BAT1308 has demonstrated a very attractive preclinical profile.” said Dr. Shengfeng Li, CEO, Bio-Thera Solutions. "We have multiple immune-oncology (IO) assets in our pipeline ta

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) has approved CABENUVA (consisting of Janssen's rilpivirine and ViiV Healthcare's cabotegravir), the first and only once-monthly, long-acting regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. The novel regimen was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen's 25-year commitment to make

Turnstone Biologics Corp., a clinical-stage biotechnology company pioneering the development of cancer immunotherapies, announced that it has acquired California-based Myst Therapeutics, a privately held biotechnology company focused on advancing novel T-cell therapies for solid tumors. The acquisition adds a pipeline of innovative TIL programs to Turnstone’s portfolio of oncolytic virus candidates. Financial terms were not disclosed. TIL therapy treatment protocols utilize po

EXACT THERAPEUTICS AS ("EXACT-Tx" or the "Company"), a clinical stage precision medicine company announced a collaboration with GE Healthcare to develop an innovative ultrasound probe to be used in forthcoming studies using Acoustic Cluster Therapy (ACT®) across multiple disease conditions. "We are delighted to collaborate with GE Healthcare, a leader in the field of diagnostic imaging and ultrasound. We look forward to working closely with GE Healthcare

Molecular Templates, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for MT-6402, a next-generation ETB targeting PD-L1 that is enabled with MTEM’s antigen seeding technology (AST). ETBs enabled with AST have dual mechanisms of action that include the

Neurophth Therapeutics, Inc., a subsidiary of Wuhan Neurophth Biotechnology Ltd. gene therapy company (hereafter Neurophth), and AAVnerGene Inc., a specializing AAV technology company, announced a strategic partnership to provide Neurophth with worldwide rights to mutually select adeno-associated virus (AAV) capsids for the next generation ophthalmic gene therapy. AAVnerGene's Tissue-specific, Highly-transductive and Expressive New AAVs (ATHENA) screening platform can efficientl

Rousselot®, a Darling Ingredients brand and the global leader of collagen-based solutions[1], introduces Peptan® Marine collagen peptides at the virtual Beauty & Skincare Formulation Conference 2021. Sourced from 100% wild-caught marine white fish and certified by the Marine Stewardship Council (MSC), this solution can help beauty and nutrition brands differentiate and expand their portfolio with sustainably-sourced, premium nutricosmetics and dietary supplements. Produced in the

Lipidor AB announced that the Company has signed an exclusive licensing agreement with Cannassure Therapeutics Ltd., an Israeli company specializing in the development and manufacture of innovative medicinal cannabis products. Under the agreement, Cannassure has the exclusive right to use Lipidor's proprietary drug delivery technology AKVANO® in medicinal cannabis products for the treatment of selected indications such as psoriasis, atopic dermatitis, pain and lesions. Lipidor receive

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases,announced an agreement with PT Etana Biotechnologies Indonesia (Etana) to out-license BYVASDA® (Bevacizumab Biosimilar)'s development and commercialization rights in Indonesia to Etana. Etana is committed to launch BYVASDA® in the local market. In return, Innovent will rec

Tessa Therapeutics (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, announced that the European Medicines Agency (EMA) has granted PRiority MEdicines (PRIME) designation to the company's lead autologous CD30 CAR-T therapy for the treatment of relapsed or refractory classical Hodgkin Lymphoma (R/R cHL). PRIME is a program launched by EMA to optimize development plans and speed up evaluatio